Mepolizumab in severe eosinophilic asthma reduces healthcare use

    This is a preview of subscription content, log in to check access.

    Notes

    1. 1.

      The analysis and the parent study were funded by GlaxoSmithKline.

    Reference

    1. Yang S, et al. Healthcare Resource use in Patients with Severe Eosinophilic Asthma after the Initiation of Mepolizumab in Real-Life Settings: REALITI-A Study. 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/101382

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Mepolizumab in severe eosinophilic asthma reduces healthcare use. PharmacoEcon Outcomes News 855, 22 (2020). https://doi.org/10.1007/s40274-020-6887-1

    Download citation